{{Short description|Chemical compound}} {{Infobox drug | drug_name = | IUPAC_name = Dimethyl ''N'',''N''′-<nowiki/>{[(2''S'',5''S'')-1-(4-''tert''-butylphenyl)pyrrolidene-2,5-diyl]-bis-<nowiki/>{[(4,1-phenyleneazanediyl)carbonyl] [(2''S'')-pyrrolidine-2,1-diyl]}[(2''S'')-3-methyl-1-oxobutane-1,2-diyl])}biscarbamate | image = Ombitasvir.svg | image_class = skin-invert-image | width = 275 | alt = | caption =
<!-- Clinical data --> | tradename = * Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir), * Technivie (with ombitasvir, paritaprevir, and ritonavir) | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category = | licence_EU = yes | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> | legal_US = Rx-only | legal_status = | routes_of_administration = By mouth (tablets)
<!-- Pharmacokinetic data --> | bioavailability = Not determined | protein_bound = ~99.9% | metabolism = Amide hydrolysis followed by oxidation | onset = ~4 to 5 hours | elimination_half-life = 21 to 25 hours | excretion = Mostly with feces (90.2%)
<!-- Identifiers --> | CAS_number = 1258226-87-7 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 2302768XJ8 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 85183 | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = 54767916 | ChemSpiderID = 31136214 | DrugBank = | synonyms = ABT-267 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D10576
<!-- Chemical data --> | C=50 | H=67 | N=7 | O=8 | smiles = CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC | StdInChI = 1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1 | StdInChIKey = PIDFDZJZLOTZTM-KHVQSSSXSA-N }}
'''Ombitasvir''' is an antiviral drug for the treatment of hepatitis C virus (HCV) infection by AbbVie. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1,<ref>{{cite web|title=VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information|url=http://www.rxabbvie.com/pdf/viekirapak_pi.pdf|publisher=AbbVie Inc., North Chicago, IL 60064|access-date=30 July 2015|archive-date=2 May 2019|archive-url=https://web.archive.org/web/20190502112917/https://www.rxabbvie.com/pdf/viekirapak_pi.pdf|url-status=dead}}</ref><ref>{{Cite web | title = FDA approves Viekira Pak to treat hepatitis C | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm | archive-url = https://web.archive.org/web/20141225030837/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm | url-status = dead | archive-date = December 25, 2014 | date = December 19, 2014 | publisher = Food and Drug Administration}}</ref> and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.<ref>{{cite web|title=TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information|url=http://rxabbvie.com/pdf/technivie_pi.pdf|publisher=AbbVie Inc., North Chicago, IL 60064|access-date=28 July 2015|archive-url=https://web.archive.org/web/20190119043452/https://www.rxabbvie.com/pdf/technivie_pi.pdf|archive-date=19 January 2019|url-status=dead}}</ref><ref>{{Cite web | title = FDA approves Technivie for treatment of chronic hepatitis C genotype 4 | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm | archive-url = https://web.archive.org/web/20150727004238/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm | url-status = dead | archive-date = July 27, 2015 | date = July 24, 2015 | publisher = Food and Drug Administration}}</ref>
Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A.<ref>{{cite journal | vauthors = Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B | display-authors = 6 | title = Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | journal = The New England Journal of Medicine | volume = 370 | issue = 17 | pages = 1594–603 | date = April 2014 | pmid = 24720703 | doi = 10.1056/NEJMoa1315722 | url = https://espace.library.uq.edu.au/view/UQ:330486/UQ330486_OA.pdf | name-list-style = amp }}</ref>
== See also == * Discovery and development of NS5A inhibitors
== References == {{reflist}}
== Further reading == {{refbegin}} * {{cite journal | vauthors = Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Wyles DL, Schnell G, Alami NN, Zhang Z, Dumas E, Dore GJ | display-authors = 6 | title = Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials | journal = Open Forum Infectious Diseases | volume = 5 | issue = 11 | pages = ofy248 | date = November 2018 | pmid = 30430131 | pmc = 6222025 | doi = 10.1007/s15010-018-1157-x | oclc = 1105037362 }} * {{cite journal | vauthors = Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A | display-authors = 6 | title = Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study | journal = The Lancet. Gastroenterology & Hepatology | volume = 2 | issue = 6 | pages = 427–434 | date = June 2017 | pmid = 28497758 | doi = 10.1016/S2468-1253(17)30048-1 | hdl = 11390/1119739 | hdl-access = free }} {{refend}}
{{RNA antivirals}}
Category:Carbamates Category:NS5A inhibitors Category:Pyrrolidines
{{Antiinfective-drug-stub}}